The Cannabinoid CB₁ Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells

CNS Research Department, Sanofi-Synthélabo Recherche, Montpellier, France

Received September 5, 2002; accepted January 14, 2002

ABSTRACT
This study investigates the effects of SR141716, a selective CB₁ receptor antagonist that reduces food intake and body weight of rodents, on Acrp30 mRNA expression in adipose tissue. Acrp30, a plasma protein exclusively expressed and secreted by adipose tissue, has been shown to induce free fatty acid oxidation, hyperglycemia and hyperinsulinemia decrease, and body weight reduction. We report that N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716) treatment once daily (10 mg/kg/d, i.p.) from 2 to 14 days reduced body weight and body weight reduction. We report that this animal model was reduced by SR141716 treatment. In cultured mouse adipocytes (3T3 F442A), SR141716 (25 to 100 nM) also induced an overexpression of Acrp30 mRNA expression in adipose tissue of obese Zucker (fa/fa) rats. In parallel, the hyperinsulinemia associated with this animal model was reduced by SR141716 treatment. In cultured mouse adipocytes (3T3 F442A), SR141716 (25 to 100 nM) also induced an overexpression of Acrp30 mRNA and protein. In addition, in adipose tissue of CB₁-receptor knockout mice, SR141716 had no effect on Acrp30 mRNA expression, demonstrating a CB₁ receptor mediating effect. Furthermore, RT-PCR analysis revealed that rat adipose tissue and 3T3 F442A adipocytes expressed CB₁ receptor mRNA. Relative quantification of this expression revealed an up-regulation (3- to 4-fold) of CB₁ receptor mRNA expression in adipose tissue of obese (fa/fa) rats and in differentiated 3T3 F442A adipocytes compared with lean rats and undifferentiated adipocytes, respectively. Western blot analysis revealed the presence of CB₁ receptors in 3T3 F442A adipocytes, and their expression was up-regulated in differentiated cells. These results show that SR141716 stimulated Acrp30 mRNA expression in adipose tissue by an effect on adipocytes, and reduced hyperinsulinemia in obese (fa/fa) rats. These hormonal regulations may participate in the body weight reduction induced by SR141716 and suggest a role of metabolic regulation in the antiobesity effect of SR141716.

Obesity is a complex metabolic disorder resulting from an abnormality in the balance between energy intake and expenditure. This dysregulation may have genetic and/or behavioral origins, involving the quality and quantity of food intake and lifestyle (Carpino, 2000). Obesity is also commonly associated with insulin resistance and hyperinsulinemia (Polonsky, 2000; Weyer et al., 2001), which increases the risk of diabetes and cardiovascular diseases (Allison et al., 1999; Must et al., 1999).

The hypothalamus is the principal brain region playing a pivotal role in the integrated control of feeding, energy homeostasis, and regulation of body weight (Elmqquist et al., 1999b; Kalra et al., 1999). This function is mediated in part by the synthesis and release of several neurotransmitters and neuropeptides involved in the control of food intake, energy expenditure, and body weight homeostasis. These include monoamine neurotransmitters, such as serotonin and noradrenaline (Halford and Blundell, 2000), orexigenic neuropeptides, such as neuropeptide Y, orexins (A and B), and anorectic peptides, such as cocaine- and amphetamine-regulated transcript and pro-opiomelanocortin-derived peptides, such as α-MSH (Kalra et al., 1999; Proietto et al., 2000). The hypothalamic CB₁ receptor antagonist also targets the site of action for the action of hormones such as insulin and leptin, which have been largely described to be involved in the regulation of food intake and body weight (Baskin et al., 1999; Elmqquist et al., 1999b; Kalra et al., 1999; Proietto et al., 2000; Williams et al., 2001).

Recently, a role for the cannabinoid receptor subtype 1 (CB₁-R) in the regulation of appetite and body weight has been reported (Di Marzo et al., 2001). There is an elevation of the level of endocannabinoids in the hypothalamus of obese animal models, and the CB₁ receptor antagonist SR141716 (Rinaldi-Carmona et al., 1994) reduces food intake and induces weight loss in mouse and rat (Arnone et al., 1997; Chaperon et al., 1998; Colombo et al., 1998; Di Marzo et al., 2001). Furthermore, after an 18-h food restriction period,

ABBREVIATIONS: CB₁-R, cannabinoid receptor 1; Acrp30, 30-kDa adipocyte complement-related protein; SR141716, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride; TBST, Tris-buffered saline Tween 20; PCR, polymerase chain reaction; RT, reverse transcriptase.
CB₁ receptor knockout mice eat less than their wild-type littermates, and SR141716 has no effect on weight gain and food intake on CB₁ receptor knockout mice (Di Marzo et al., 2001). These findings suggest a physiological role for the hypothalamic CB₁ receptor in the control of appetite. They also indicate that endocannabinoids, in the hypothalamus, may tonically activate CB₁ receptors to maintain food intake and to sustain overeating in obese animals (Colombo et al., 1998; Di Marzo et al., 2001).

The reported loss of body weight induced by SR141716 results in part from its rapid and strong decrease of food intake during the first days of treatment (Colombo et al., 1998; Di Marzo et al., 2001). This effect may be mediated by a mechanism involving the regulation of the expression of hypothalamic neuropeptides (Proietto et al., 2000). Furthermore, the long-lasting loss of body weight induced by SR141716 may be independent of food intake and is likely to be related to an increase in energy expenditure and/or metabolic activities.

The site of action of SR141716 with regard to a potential peripheral effect could be the adipose tissue, which is the major fat storage depot. This endocrine organ produces and secretes various physiologically important proteins, such as leptin, adipin, lipoprotein lipase, and tumor necrosis factor α, which regulate whole-body energy homeostasis (Dugail et al., 1992; Fried and Russell, 1998).

One of these proteins, the 30-kDa adipocyte complement-related protein (Acrp30) originally identified by four independent groups (Hu et al., 1996; Maeda et al., 1996; Nakano et al., 1996; Scherer et al., 1995), also known as adiponectin, Adipo Q, and ApM1, is exclusively expressed in the adipose tissue. Acrp30 is a secreted protein, with an N-terminal collagenous domain and a C-terminal globular domain. The latter domain carries all the known pharmacological activities of Acrp30, comprising the induction of free fatty acid oxidation, body weight reduction in mice (Fruebis et al., 2001), hyperglycemia (Berg et al., 2001; Combs et al., 2001), hyperinsulinemia decrease, and insulin resistance reversion (Yamauchi et al., 2001) in obese and diabetic animals. Furthermore, the plasma level of the protein Acrp30 and its mRNA expression in adipose tissue are decreased in both murine and human obesity, as well as in subjects with type 2 diabetes (Hu et al., 1996; Arita et al., 1999; Fruebis et al., 2001; Weyer et al., 2001).

The aim of the present work was to determine whether SR141716 affects the regulation of Acrp30 mRNA expression in adipose tissue and to provide evidence for the implication of peripheral CB₁ receptors in the control of body weight.

**Materials and Methods**

**Animals and Adipose Tissue.** Male obese Zucker (fa/fa) rats and their lean littermates of 8 to 9 weeks of age were purchased from Harlan (Indianapolis, IN). C57BL/6j mice with deleted CB₁ receptor gene (CB₁-R −/−) and wild-type C57BL/6j mice (CB₁-R +/+ ) were bred as described previously (Robbe et al., 2002) and used at 9 to 10 weeks of age. All animals were housed in groups of six with food and water freely available and were maintained at room temperature.

Animals were administered once a day, with either vehicle or SR141716 at tested doses (3 or 10 mg/kg/d) by intraperitoneal injection (i.p.) for different periods of treatment (from 2 to 14 days). They were killed by decapitation 24 h after the last injection. Abdominal subcutaneous adipose tissues were collected, pooled by groups of six animals, and frozen immediately at −80°C. After the rats were killed, individual trunk blood was collected for determining plasma levels of insulin by radioimmunoassay as described in the manufacturer's protocol (Amersham Biosciences, Les Ulis, France). All procedures were approved by the Comité d’Expérimentation Animale (Animal Care and Use Committee) of Sanofi-Synthélabo Research.

**Cell Culture.** Mouse 3T3 F442A cells (Green and Kehinde, 1973; Kuri-Harcuch and Green, 1977) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% calf serum and differentiated with DMEM supplemented with 10% fetal calf serum and 5 μg/ml of insulin after reaching confluence as described previously (Hu et al., 1996). Appropriate differentiation was confirmed by noting the accumulation of lipid droplets by microscopic observation, 6 to 8 days after the initiation of differentiation.

**RNA Preparation and Northern Blot Analysis.** β Actin cDNA probe was purchased from BD Biosciences Clontech (Palo Alto, CA). Rat and mouse Acrp30 cDNA probes were obtained by RT-PCR on adipose tissue RNA according to the manufacturer's protocol (Invitrogen, Cergy Pontoise, France) in the presence of two Acrp30 cDNA-specific primers (sense primer, 5′-CAG GAT GCT ACT GTT GCA AGC-3′; antisense primer, 5′-TGC AGT CAG TGT TGA TCA TGG-3′) spanning the start and stop codons, respectively, in the sequence of the mouse Acrp30 cDNA (GenBank accession number U37222).

Total RNA was prepared from frozen adipose tissues or from adipocyte 3T3 F442A cell cultures, using TRIzol reagent (Invitrogen). For Northern blot analysis, 20 μg of total RNA was electrophoresed and transferred to a nylon membrane (Hybond N⁺; Amersham Biosciences). The membranes were hybridized successively with Acrp30 and β actin probes labeled with [α-32P]dCTP, using a random priming kit (Amersham Biosciences).

Membranes were scanned on a Storm PhosphorImager (Amersham Biosciences). Northern blot analysis revealed the expression of one and three Acrp30 transcripts in mouse and rat tissues, respectively, as reported previously (Hu et al., 1996). Relative quantification of RNA expression levels was performed with the IMAGE-QuanNT program (Amersham Biosciences). Results were normalized against the β actin mRNA expression and were presented as a percentage of control values.

**RT-PCR Analysis of CB₁ Receptor Expression.** For RT-PCR, 2 μg of total RNA from rat adipose tissues and 3T3 F442A cells were reverse-transcribed using oligo(dT) primer, and PCR amplification of the first-strand cDNA product was carried out according to the manufacturer’s protocol (Invitrogen) in the presence of either two CB₁ receptors cDNA-specific primers (sense primer, 5′-CTC CTG GAA GGC TCA CAG C-3′; antisense primer, 5′-TGT CTG TGG ACA CAG ACA TG-3′) or two β-actin cDNA-specific primers (sense primer, 5′-GGG TCA CCC ACA CTG TGC-3′; antisense primer, 5′-TGG TTC CTG CTG ATC CAC ATC TG-3′). The following temperature profile was used for PCR amplification: an initial denaturing step at 93°C for 1 min and 35 cycles consisting of 93°C for 30 s, 55°C for 30 s, and 72°C for 1 min. PCR products were analyzed by Southern blot using a 32P-labeled oligonucleotide probe specific for CB₁ receptor or β actin cDNA. The relative mRNA expression levels of CB₁ receptor and β actin were quantified using the Storm PhosphorImager system. Results were normalized and presented as described above.

**Western Blot Analysis.** 3T3 F442A adipocyte cellular proteins were dissloved in the lysis buffer: 50 mM Tris HCl, pH 7.5, 1% SDS, 10 mM EDTA, 100 mM NaCl, and 1% β-mercaptoethanol containing protease inhibitors (Roche Diagnostics, Mannheim Germany), and centrifuged at 12,000g for 15 min at 4°C. The supernatants were collected and protein concentrations were determined by bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Cellular protein extracts (200 μg) were analyzed on the NOVEX precast 4 to 20% Tris-glycine-SDS-polyacrylamide gel electrophoresis gels and transferred on polyvinylidene difluoride membranes as indicated by the manufacturer (Novex, San Diego, CA). The following steps were performed at room temperature. The membranes were blocked with
SB141716 Reduced Body Weight of Obese Zucker (fa/fa) Rats. Obese (fa/fa) rats showed a rapid body weight reduction during the first 4 days of treatment with SB141716 (10 mg/kg/d). Body weight was reduced up to 20% on day 4 compared with the initial body weight at day 0 (Fig. 1). These results agree with those reported previously (Colombo et al., 1998). Furthermore, after the fourth day of treatment and throughout the complete treatment period, body weight of SB141716-treated rats continued to be lower than that of vehicle-treated rats (Fig. 1), whereas food intake of SB141716-treated rats became comparable with that of lean rats (Colombo et al., 1998; M. Arnone, L. Millet, M. F. Desclaux, C. Delgorge, P. Keane, J. P. Maffrand, P. Soubrie, submitted). This suggests a metabolic and energy expenditure regulation by SB141716 in addition to its early reduction of food intake.

SB141716 Increased Acrp30 mRNA Expression in Adipose Tissue of Obese Zucker (fa/fa) Rats. The expression of Acrp30 was increased by 1.33- and 1.37-fold in adipose tissue of obese (fa/fa) rats treated once daily, by vehicle or by SB141716 at 3 and 10 mg/kg/d, respectively, compared with the initial body weight at day 0 (Fig. 1). These results agree with those reported previously (Colombo et al., 1998). Furthermore, after the fourth day of treatment and throughout the complete treatment period, body weight of SB141716-treated rats continued to be lower than that of vehicle-treated rats (Fig. 1), whereas food intake of SB141716-treated rats became comparable with that of lean rats (Colombo et al., 1998; M. Arnone, L. Millet, M. F. Desclaux, C. Delgorge, P. Keane, J. P. Maffrand, P. Soubrie, submitted). This suggests a metabolic and energy expenditure regulation by SB141716 in addition to its early reduction of food intake.

SB141716 Stimulated Acrp30 mRNA and Protein Expression in Cultured Mouse 3T3 F442A Adipocyte Cells. The addition of SB141716 (100 nM) to subconfluent cultures of 3T3 F442A adipocytes, induced a rapid and strong increase in Acrp30 expression. As shown in Fig. 4A, the stimulation rate of Acrp30 mRNA expression, compared with that of control cultures, was 1.4- and 1.8-fold after 30 and 60 min of SB141716 incubation, respectively. At 60 min of treatment, SB141716 increased Acrp30 expression in a concentration-dependent manner from 25 to 200 nM with a maximal effect at 100 nM (Fig. 4B). In parallel, after 4 days of treatment, SB141716 increased in a concentration-dependent manner (from 50 to 200 nM) the level of the protein Acrp30 in 3T3 F442A adipocytes, with a maximal effect at 100 nM (Fig. 4C).

Results

SR141716 Reduced Body Weight of Obese Zucker (fa/fa) Rats. Obese (fa/fa) rats showed a rapid body weight reduction during the first 4 days of treatment with SB141716 (10 mg/kg/d). Body weight was reduced up to 20% on day 4 compared with the initial body weight at day 0 (Fig. 1). These results agree with those reported previously (Colombo et al., 1998). Furthermore, after the fourth day of treatment and throughout the complete treatment period, body weight of SB141716-treated rats continued to be lower than that of vehicle-treated rats (Fig. 1), whereas food intake of SB141716-treated rats became comparable with that of lean rats (Colombo et al., 1998; M. Arnone, L. Millet, M. F. Desclaux, C. Delgorge, P. Keane, J. P. Maffrand, P. Soubrie, submitted). This suggests a metabolic and energy expenditure regulation by SB141716 in addition to its early reduction of food intake.

SR141716 Increased Acrp30 mRNA Expression in Adipose Tissue of Obese Zucker (fa/fa) Rats. The expression of Acrp30 was increased by 1.33- and 1.37-fold in adipose tissue of obese (fa/fa) rats treated once a day for 4 days with SB141716 at 3 and 10 mg/kg/d, respectively, compared with control animals that received vehicle (Fig. 2). The rate of stimulation of Acrp30 expression induced by SB141716 was dependent on the duration of the treatment. At a dose of SB141716 (10 mg/kg/d), there was a 1.37- and 1.8-fold increase in Acrp30 expression after 4 and 10 days of treatment, respectively. This level of expression remained constant until day 14 (Fig. 3A). No effect of SB141716 was observed before day 4 (data not shown).

In adipose tissue of lean Zucker rats, SB141716 (10 mg/kg/d) had no detectable effect on Acrp30 expression after 4 days of treatment, but there was a slight but significant increase (1.25-fold) in Acrp30 expression after 10 or 14 days of treatment (Fig. 3B).

SR141716 Stimulated Acrp30 mRNA and Protein Expression in Cultured Mouse 3T3 F442A Adipocyte Cells. The addition of SB141716 (100 nM) to subconfluent cultures of 3T3 F442A adipocytes, induced a rapid and strong increase in Acrp30 expression. As shown in Fig. 4A, the stimulation rate of Acrp30 mRNA expression, compared with that of control cultures, was 1.4- and 1.8-fold after 30 and 60 min of SB141716 incubation, respectively. At 60 min of treatment, SB141716 increased Acrp30 expression in a concentration-dependent manner from 25 to 200 nM with a maximal effect at 100 nM (Fig. 4B). In parallel, after 4 days of treatment, SB141716 increased in a concentration-dependent manner (from 50 to 200 nM) the level of the protein Acrp30 in 3T3 F442A adipocytes, with a maximal effect at 100 nM (Fig. 4C).

CB1 Receptor Mediated the SB141716-Stimulation of Acrp30 Expression in Adipose Tissue. In adipose tissue of wild-type mice (CB1-R +/+), SB141716 (10 mg/kg/d) induced a slight and significant increase of the Acrp30 expression (1.25-fold) after 10 days of treatment (Table 1). This SB141716 stimulation rate is comparable with that observed in lean Zucker rats (Fig. 3B). By contrast, as shown in Table 1, once-daily treatment with SB141716 (10 mg/kg/d) for 4 or 10 days did not induce any effect on Acrp30 expression in adipose tissue of CB1 receptor knockout mice (CB1-R −/−).
CB₁ Receptor Expression Analysis in Rat Adipose Tissue and in Mouse 3T3 F442A Adipocyte Cells. CB₁ receptor expression was assessed by RT-PCR analysis, using specific oligonucleotide primers, on mRNA isolated from rat adipose tissues of obese (fa/fa) and lean Zucker rats and from undifferentiated and differentiated 3T3 F442A adipocyte cells in culture. As shown in Fig. 5, A and B, all these tissues and cells expressed CB₁ receptor mRNA. Relative quantification analysis of this CB₁ receptor expression, normalized against that of β actin, revealed an up-regulation of the CB₁ receptor expression in adipose tissue of obese rats which was 3.11-fold higher than that observed in lean rats. Furthermore, in differentiated 3T3 F442A adipocyte cells, the expression of CB₁ receptor mRNA was 4.35-fold higher than that obtained in undifferentiated adipocytes. The fact shows that CB1 receptor was present in 3T3 F442A adipocyte cells and that its level was 4.9 fold higher in differentiated adipocyte cells compared with the level observed in undifferentiated cells shown in Fig. 5C.

SR141716 Decreased Hyperinsulinemia in Obese Zucker (fa/fa) Rats. We also investigated the effect of SR141716 on the hyperinsulinemia characterizing obese Zucker (fa/fa) rats. Once daily treatment of obese (fa/fa) rats with SR141716 (10 mg/kg/d, i.p.) for 4 days, induced a strong decrease in plasma insulin rate (60%) in comparison with the insulin rate of control animals that received vehicle (Fig. 6). In contrast, SR141716 treatment in the same condition had no effect on the plasma insulin levels of lean Zucker rats (Fig. 6).

Discussion

Recently, it has been reported that SR141716, a selective CB₁-receptor antagonist, reduced body weight of genetically obese Zucker (fa/fa) rats (M. Arnone, L. Millet, M. F. Desclaux, C. Delgorge, P. Keane, J. P. Maffrand, P. Soubrié, submitted). This SR141716-induced body weight loss seems to comprise two phases. The early phase is principally food intake-regulation-dependent: during the first days of treatment, SR141716 reduced both food intake and body weight. This SR141716-induced body weight loss may originate from the decrease of food intake, which may itself be mediated by a regulation of the expression and release of hypothalamic neuropeptides involved in both the control of appetite and body-weight regulation (i.e., a central effect of SR141716) (Elmquist et al., 1999; Kalra et al., 1999; Proietto et al., 2000).

The second phase is food intake-regulation-independent: after the early phase (4 days of treatment) and throughout the entire period of treatment, SR141716-induced body weight loss was maintained, whereas food intake returned to a level comparable with that of nonobese (lean) rats. These results agree with those reported previously (Colombo et al., 1998; M. Arnone, L. Millet, M. F. Desclaux, C. Delgorge, P. Keane, J. P. Maffrand, P. Soubrié, submitted) and suggest a metabolic and energy expenditure regulation by long term SR141716-treatment.

Acrp30 is a plasma protein exclusively expressed in adipose tissue and has been reported to regulate hyperglycemia, hyperinsulinemia and fatty acid oxidation (Berg et al., 2001; Combs et al., 2001; Fruebis et al., 2001; Yamachi et al., 2001). Intravenous injection of Acrp30 reduced body weight in obese animals, in a food intake-independent manner (Fruebis et al., 2001). Furthermore, both the plasma levels and adipose tissue mRNA of Acrp30 are decreased in obese subjects (Hu et al., 1996; Arita et al., 1999; Fruebis et al., 2001; Weyer et al., 2001). Therefore, we investigated the effect of SR141716 on Acrp30 mRNA expression in adipose tissue. Our results show that, after 4 days of treatment, SR141716 stimulated Acrp30 mRNA expression in adipose tissue of obese Zucker (fa/fa) rats. This stimulation was also found to occur within 30 min of SR141716 treatment of cultured mouse 3T3 F442A adipocyte cells. Furthermore, like Acrp30 mRNA, SR141716 treatment also increased Acrp30 protein levels in mouse 3T3 F442A adipocyte cells.

We also show that in adipose tissue of wild-type mice, SR141716 induced an up-regulation of Acrp30 mRNA expression with a level of stimulation comparable with that observed in lean Zucker rats. In contrast, SR141716 had no effect on Acrp30 mRNA expression in adipose tissue of CB₁ knockout mice (CB₁–/–). These results demonstrated that SR141716 regulates Acrp30 expression in adipocytes.
through a CB₁ receptor-mediated pathway, but the mechanism involved in this SR141716 effect remains to be fully elucidated.

Using RT-PCR analysis, we provide evidence that adipose tissue of lean and obese rats and cultured mouse 3T3 F442A adipocyte cells express the CB₁ receptor and protein. Additionally, CB₁ receptor expression is up-regulated in adipose tissue of obese (fa/fa) rats and in differentiated mouse 3T3 F442A adipocyte cells.

Together, these results suggest a role for adipose tissue CB₁ receptors in the control of body weight homeostasis, as illustrated by the effects of the CB₁ receptor antagonist.

![Image of Western blot results showing the expression of Acrp30 and β-actin in response to SR141716 treatment.](attachment:image.png)

**Fig. 4.** Effect of SR141716 on Acrp30 expression in mouse 3T3 F442A adipocyte cells. Mouse 3T3 F442 adipocyte cells were cultured in DMEM supplemented with 10% calf serum. At subconfluence, culture medium was changed and cells were exposed or not (control) to 100 nM SR141716. At indicated times, total cellular mRNA were prepared and analyzed by Northern blot as described under Materials and Methods. A, representative Northern blot analysis. Bar graph shows results of quantification analysis of Acrp30 expression normalized against the expression levels of β-actin. Values represent mean ± S.E.M. from three independent experiments. **, p < 0.01, compared with control. B, concentration-dependent effect of SR141716 (at 60 min at the treatment) on Acrp30 mRNA expression. C, concentration-dependent effect of SR141716 on Acrp30 protein level. Subconfluent mouse 3T3 F442A adipocytes were exposed or not (control) to various concentrations of SR141716 (50 to 200 nM) every day for 4 days. Cellular protein extracts were analyzed by Western blot using rabbit anti-mouse Acrp30 antibody at 1:1000. Values represent the mean ± S.E.M. from three independent experiments. *, p < 0.05; **, p < 0.01, compared with control.
SR141716, and agree with those reported previously (Di Marzo et al., 2001).

Hyperinsulinemia and insulin resistance are commonly associated with obesity (Allison et al., 1999; Must et al., 1999; Polonsky, 2000) and with a decrease of Acrp30 plasma levels (Weyer et al., 2001). In parallel to the increase of Acrp30 mRNA expression in adipose tissue, SR141716 treatment decreased the hyperinsulinemia characterizing obese (fa/fa) rats. This effect may involve a direct action of SR141716 on plasma insulin levels of obese (fa/fa) rats or may be mediated by the stimulation of Acrp30, which has been shown to decrease hyperinsulinemia and reverse insulin resistance (Yamauchi et al., 2001). Whatever the mechanism involved

<table>
<thead>
<tr>
<th>Mice</th>
<th>Ratio Acrp30 mRNA SR141176-Treated/Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean fa/fa</td>
<td>1.15 ± 0.06</td>
</tr>
<tr>
<td>U</td>
<td>0.95 ± 0.11</td>
</tr>
<tr>
<td>D</td>
<td>0.85 ± 0.10</td>
</tr>
</tbody>
</table>

*, P < 0.05 compared with control.

Fig. 5. RT-PCR analysis of CB1 receptor mRNA expression. Total RNA isolated from adipose tissues of obese Zucker (fa/fa) rats or their lean littersmates (lean) and from differentiated (D) or undifferentiated (U) 3T3 F442A adipocyte cells were reverse transcribed and submitted to PCR amplification, using sense and antisense primers specific for CB1 receptor cDNA or for β actin cDNA. RT-PCR products were analyzed by Southern blot and probed with a 32P-labeled internal oligonucleotide probe specific for CB1 receptor or for β actin cDNA. CB1 receptor expression, normalized against that of β actin was quantified by using IMAGE QuanNT program (Amersham Biosciences). A, representative RT-PCR analysis. B, bar graph shows results of quantification analysis. C, Western blot analysis of CB1-R levels in 3T3 F442A adipocyte cells. Cellular proteins extracted from differentiated (D) and undifferentiated (U) adipocytes were analyzed by Western blot using rabbit anti-mouse CB1-R antibody at 1:500. Values represent mean ± S.E.M. from two independent experiments.
in the effects of SR141716, the decrease of hyperinsulinemia may participate to the overall action of SR141716 on body weight regulation. This hypothesis agrees with the proposal that decreasing hyperinsulinemia may be a therapeutic approach to treat obesity, in particular that associated with type 2 diabetes (Campfield et al., 1995).

In summary, SR141716 stimulated Acrp30 mRNA expression in adipose tissue and decreased hyperinsulinemia in obese Zucker (fa/fa) rats. The regulation by SR141716 of a protein involved in lipid metabolism (Acrp30) and of a metabolic hormone (insulin) suggests that these factors may be among the principal mediators of the metabolic effects of SR141716 leading to body weight reduction and indicates that SR141716 may antagonize an endogenous endocannabinoid tone or could exert this effect by its agonist inverse activity previously described (Bouaboula et al., 1997). Other enzymes and hormones may also participate in these metabolic effects of SR141716.

Finally, our data demonstrate for the first time that SR141716 regulates hormones implicated in lipid and glucose metabolism and clearly underline that SR141716 could exert a metabolic “peripheral” action in addition to its known “central” effect on food intake. The regulation of food intake and body weight by SR141716 may result from these closely related and complementary effects.

Acknowledgments
We thank Ruth LeGué for typing the manuscript, Isabel Lefevre for criticism and helpful comments, and John Alexander for editing the article.

References

Address correspondence to: Mohamed Bensaid, Sanofi-Synthélabo Recherche, CNS Research Department, 371 rue du Professeur J. Blayac, F-34184 Montpellier Cédex 04, France. E-mail: mohamed.bensaid@sanofi-synthelabo.com.